Cantargia is a clinical stage biotechnology company based in Sweden, established in 2009 and listed on Nasdaq Stockholm main market. It is developing antibodies against IL1RAP (CAN04 and CAN10). CAN04 is being studied in a Phase I/IIa CANFOUR in solid tumours, while CAN10 is a preclinical project in inflammatory diseases.
Cantargia is developing antibodies against IL1RAP. In December 2019, it reported interim data from the ongoing three-arm Phase IIa study with CAN04 in combination with first-line chemotherapy in NSCLC and pancreatic cancer (PDAC). Four out of seven evaluable PDAC patients achieved partial response and two out of three evaluable NSLC patients achieved an objective response (one complete and one partial). The results compare favourably to historical response rates to standalone chemotherapy regimens (23% in PDAC; 22–28% in first-line NSCLC). More interim data will be presented in 2020, while final results are expected in 2021. Cantargia also plans to initiate a Phase Ib trial in the US with CAN04 in combination with a CPI. Cantargia introduced CAN10, a preclinical project in inflammation uniquely targeting three interleukins, IL-1, IL-33 and IL-36. In February 2020, Cantargia raised SEK410m. We are revising our financial estimates.
Increasing the understanding of inflammation in malignant processes now includes findings that cytokines are not only produced by the immune cells, but that cancer itself can produce certain cytokines and the associated receptors to escape from the immune response. Therefore, cytokines represent potentially promising class of targets in oncology.